DEK Depletion Negatively Regulates Rho/ROCK/MLC Pathway in Non-Small Cell Lung Cancer

Journal of Histochemistry and Cytochemistry

Volumn 61, Issue 7, 2013, Pages 510-521

  Wang, Junying ^a   Sun, Limei ^a   Yang, Mingyue ^a   Luo, Wenting ^a   Gao, Ying ^a   Liu, Zihui ^a   Qiu, Xueshan ^a   Wang, Enhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

apoptosis; DEK; migration; oncogenic; proliferation; RhoA

Indexed keywords

DEK PROTO ONCOGENE PROTEIN; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 2; NUCLEAR PROTEIN; PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ROCK PROTEIN; UNCLASSIFIED DRUG; CARDIAC MYOSIN; DEK PROTEIN, HUMAN; NONHISTONE PROTEIN; ONCOPROTEIN; RHO KINASE;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE DIFFERENTIATION; AGED; APOPTOSIS; CELL MOTION; DEK; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MIGRATION; ONCOGENIC; PATHOLOGY; PROLIFERATION; RHOA; TUMOR CELL LINE;

APOPTOSIS; DEK; MIGRATION; ONCOGENIC; PROLIFERATION; RHOA;

ADULT; AGED; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CARDIAC MYOSINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYOSIN LIGHT CHAINS; ONCOGENE PROTEINS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84882969471     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155413488120     Document Type: Article

References (34)

1. Alexiadis V,Waldmann T,Andersen J,Mann M,Knippers R,Gruss C.The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner.Genes Dev. 2000;14:1308-1312.
2. Amano M,Ito M,Kimura K,Fukata Y,Chihara K,Nakano T,Matsuura Y,Kaibuchi K.Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase).J Biol Chem. 1996;271:20246-20249.
3. Campillos M,Garcia MA,Valdivieso F,Vazquez J.Transcriptional activation by AP-2alpha is modulated by the oncogene DEK.Nucleic Acids Res. 2003;31:1571-1575.
4. Carro MS,Spiga FM,Quarto M,Di Ninni V,Volorio S,Alcalay M,Müller H.DEK expression is controlled by E2F and deregulated in diverse tumor types.Cell Cycle. 2006;5:1202-1207.
5. Casas S,Nagy B,Elonen E,Aventín A,Larramendy ML,Sierra J,Ruutu T,Knuutila S.Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia.Leuk Lymphoma. 2003;44:1935-1941.
6. Evans AJ,Gallie BL,Jewett MA,Pond GR,Vandezande K,Underwood J,Fradet Y,Lim G,Marrano P,Zielenska M, et al.Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction.Am J Pathol. 2004;164:285-293.
7. Farray D,Mirkovic N,Albain KS.Multimodality therapy for stage III non-small-cell lung cancer.J Clin Oncol. 2005;23:3257-3269.
8. Grasemann C,Gratias S,Stephan H,Schüler A,Schramm A,Klein-Hitpass L,Rieder H,Schneider S,Kappes F,Eggert A, et al.Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma.Oncogene. 2005;24:6441-6449.
9. Hirata K,Kikuchi A,Sasaki T,Kuroda S,Kaibuchi K,Matsuura Y,Seki H,Saida K,Takai Y.Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction.J Biol Chem. 1992;267:8719-8722.
10. Horiuchi A,Kikuchi N,Osada R,Wang C,Hayashi A,Nikaido T,Konishi I.Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with lovastatin may be useful for ovarian cancer.Cancer Sci. 2008;12:2532-2539.
11. Kappes F,Waldmann T,Mathew V,Yu J,Zhang L,Khodadoust MS,Chinnaiyan AM,Luger K,Erhardt S,Schneider R, et al.The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity.Genes Dev. 2011;25:673-678.
12. Katoh K,Kano Y,Amano M,Onishi H,Kaibuchi K,Fujiwara K.Rho-kinase-mediated contraction of isolated stress fibers.J Cell Biol. 2001;153:569-584.
13. Kavanaugh GM,Wise-Draper TM,Morreale RJ,Morrison MA,Gole B,Schwemberger S,Tichy ED,Lu L,Babcock GF,Wells JM, et al.The human DEK oncogene regulates DNA damage response signaling and repair.Nucleic Acids Res. 2011;39:7465-7476.
14. Khodadoust MS,Verhaegen M,Kappes F,Riveiro-Falkenbach E,Cigudosa JC,Kim DS,Chinnaiyan AM,Markovitz DM,Soengas MS.Melanoma proliferation and chemoresistance controlled by the DEK oncogene.Cancer Res. 2009;69:6405-6413.
15. Kondoh N,Wakatsuki T,Ryo A,Hada A,Aihara T,Horiuchi S,Goseki N,Matsubara O,Takenaka K,Shichita M, et al.Identification and characterization of genes associated with human hepatocellular carcinogenesis.Cancer Res. 1999;59:4990-4996.
16. Kroes RA,Jastrow A,McLone MG,Colley P,Kersey DS,Yong VW,Mkrdichian E,Cerullo L,Leestma J, et al.The identification of novel therapeutic targets for the treatment of malignant brain tumors.Cancer Lett. 2000;156:191-198.
17. Larramendy ML,Niini T,Elonen E,Nagy B,Ollila J,Vihinen M,Knuutila S.Overexpression of translocation associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia: a microarray analysis.Haematologica. 2002;87:569-577.
18. Orlic M,Spencer CE,Wang L,Gallie BL.Expression analysis of 6p22 genomic gain in retinoblastoma.Genes Chromosomes Cancer. 2006;45:72-82.
19. Paderova J,Orlic-Milacic M,Yoshimoto M,da Cunha Santos G,Gallie B,Squire JA.Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses.Cancer Genet Cytogenet. 2007;179:102-111.
20. Paterson HF,Self AJ,Garrett MD,Just I,Aktories K,Hall A.Microinjection of recombinant p21rho induces rapid changes in cell morphology.J Cell Biol. 1990;111:1001-1007.
21. Prendergast GC,Khosravi-Far R,Solski PA,Kurzawa H,Lebowitz PF,Der CJ.Critical role of Rho in cell transformation by oncogenic Ras.Oncogene. 1995;10:2289-2296.
22. Privette Vinnedge LM,McClaine R,Wagh PK,Wikenheiser-Brokamp KA,Waltz SE,Wells SI.The human DEK oncogene stimulates beta-catenin signaling, invasion and mammosphere formation in breast cancer.Oncogene. 2011;30:2741-2752.
23. Reed MF,Molloy M,Dalton EL,Howington JA.Survival after resection for lung cancer is the outcome that matters.Am J Surg. 2004;188:598-602.
24. Rooney C,Sethi T.The epithelial cell and lung cancer: the link between chronic obstructive pulmonary disease and lung cancer.Respiration. 2011;81:89-104.
25. Sawatsubashi S,Murata T,Lim J,Fujiki R,Ito S,Suzuki E,Tanabe M,Zhao Y,Kimura S,Fujiyama S, et al.A histone chaperone, DEK, transcriptionally coactivates a nuclear receptor.Genes Dev. 2010;24:159-170.
26. Schiller JH,Harrington D,Belani CP,Langer C,Sandler A,Krook J,Zhu J,Johnson DH.Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med. 2002;346:92-98.
27. Soares LM,Zanier K,Mackereth C,Sattler M,Valcarcel J.Intron removal requires proofreading of U2AF/3′ splice site recognition by DEK.Science. 2006;312:1961-1965.
28. Soekarman D,von Lindern M,Daenen S,de Jong B,Fonatsch C,Heinze B,Bartram C,Hagemeijer A,Grosveld G.The translocation (6;9) (p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features.Blood. 1992;79:2990-2997.
29. Takaishi K,Kikuchi A,Kuroda S,Kotani K,Sasaki T,Takai Y.Involvement of rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in cell motility.Mol Cell Biol. 1993;13:72-79.
30. Ueda K,Murata-Hori M,Tatsuka M,Hosoya H.Rho-kinase contributes to diphosphorylation of myosin II regulatory light chain in nonmuscle cells.Oncogene. 2002;21:5852-5860.
31. von Lindern M,Fornerod M,van Baal S,Jaegle M,de Wit T,Buijs A,Grosveld G.The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA.Mol Cell Biol. 1992;12:1687-1697.
32. Wilkinson S,Paterson HF,Marshall CJ.Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion.Nat Cell Biol. 2005;7:255-261.
33. Wise-Draper TM,Allen HV,Jones EE,Habash KB,Matsuo H,Wells SI.Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.Mol Cell Biol. 2006;26:7506-7519.
34. Yoshioka K,Nakamori S,Itoh K.Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells.Cancer Res. 1999;59:2004-2010.